Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Lessened by First National Bank of Omaha

First National Bank of Omaha lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,987 shares of the specialty pharmaceutical company’s stock after selling 2,505 shares during the period. First National Bank of Omaha’s holdings in Jazz Pharmaceuticals were worth $3,341,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. CWA Asset Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the last quarter. Swedbank AB acquired a new position in shares of Jazz Pharmaceuticals in the second quarter worth $106,936,000. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares during the last quarter. Finally, Philip James Wealth Mangement LLC acquired a new position in Jazz Pharmaceuticals during the third quarter worth $830,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,753 shares of company stock worth $816,289 over the last quarter. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.4 %

Shares of JAZZ opened at $122.59 on Monday. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of 17.27, a P/E/G ratio of 1.04 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a 50-day moving average price of $116.18 and a two-hundred day moving average price of $111.63.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Piper Sandler reissued an “overweight” rating and set a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC reissued a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.